The place of placebo? The ethics of placebo-controlled trials in bipolar disorder

Acta Neuropsychiatrica

Volumn 19, Issue 2, 2007, Pages 74-75

  Berk, Michael ^a,b,c  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b THE NATIONAL CENTRE OF EXCELLENCE IN YOUTH MENTAL HEALTH   (Australia)

^c FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; LITHIUM; OLANZAPINE; PLACEBO; QUETIAPINE; VALPROIC ACID;

BIPOLAR DISORDER; CLINICAL RESEARCH; DEPRESSION; EDITORIAL; HUMAN; MEDICAL AUDIT; MEDICAL ETHICS; PRACTICE GUIDELINE; PSYCHOPHARMACOLOGY; REFERENCE DATABASE; RISK ASSESSMENT; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 34247111891     PISSN: 09242708     EISSN: 16015215     Source Type: Journal    
DOI: 10.1111/j.1601-5215.2007.00191.x     Document Type: Editorial

References (13)

1. ENSERINK M. Can the placebo be the cure? Science 1999;284:238-240.
2. YOUNG SN, ANNABLE L. The use of placebos in psychiatry: a response to the draft document prepared by the Tri-Council Working Group. Canadian College of Neuropsychopharmacology. J Psychiatry Neurosci 1996;21:235-238.
3. MUDUR G. Indian study sparks debate on the use of placebo in psychiatry trials. BMJ 2006;332:566.
4. KIM SY. Benefits and burdens of placebos in psychiatric research. Psychopharmacology (Berl) 2003;171:13-18.
5. CARPENTER WT Jr, SCHOOLER NR, KANE JM. The rationale and ethics of medication-free research in schizophrenia. Arch Gen Psychiatry 1997;54:401-407.
6. KAMLET MS, PAUL N, GREENHOUSE J et al. Cost utility analysis of maintenance treatment for recurrent depression. Control Clin Trials 1995;16:17-40.
7. MURRAY CJ, LOPEZ AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997;349:1498-1504.
8. BOWDEN CL, CALABRESE Jr, MCELROY SL et al. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group. Arch Gen Psychiatry 2000;57:481-489.
9. LAUGHREN TP. The scientific and ethical basis for placebocontrolled trials in depression and schizophrenia: an FDA perspective. Eur Psychiatry 2001;16:418-423.
10. WALSH BT, SEIDMAN SN, SYSKO R, GOULD M. Placebo response in studies of major depression: variable, substantial, and growing. JAMA 2002;287:1840-1847.
11. LAKOFF A. The mousetrap: managing the placebo effect in antidepressant trials. Mol Interv 2002;2:72-76.
12. JOHNSON RE, MCFARLAND BH. Lithium use and discontinuation in a health maintenance organization. Am J Psychiatry 1996;153:993-1000.
13. BALDESSARINI RJ, LEAHY L, ARCONA S et al. Patterns of psychotropic drug prescription for U.S. patients with diagnoses of bipolar disorders. Psychiatr Serv 2007;58:85-91.